Pineda AM, et al. - Among patients randomized to TAVR or SAVR in the CoreValve US Pivotal High Risk Trial, researchers compared mid-term outcomes between both groups in relation to the presence of chronic kidney disease (CKD). Retrospective stratification by eGFR as either none/mild or moderate/severe CKD was done. They assessed the influence of baseline CKD in only TAVR patients by stratifying all patients undergoing an attempted TAVR implant in the US Pivotal Trial and CAS by baseline eGFR into none/mild, moderate, and severe CKD. Major adverse cardiovascular and renal events (MACRE), a composite of all-cause mortality, myocardial infarction, stroke/TIA, and new requirement of dialysis was the primary endpoint. In high-risk patients with moderate/severe CKD, a lower 3-year MACRE was observed in relation to TAVR vs SAVR. Increased mid-term mortality and MACRE were reported in association with worsening CKD in patients undergoing TAVR.